CVS Health Reports Record Third Quarter Results

Go back to CVS Health Reports Record Third Quarter Results

Margin Pressures Could Weigh on CVS Health (CVS) Shares; Oppenheimer Cuts Price Target to $115

November 2, 2015 11:16 AM EST

Oppenheimer maintained an Outperform rating on CVS Health (NYSE: CVS), and cut the price target to $115.00 (from $122.00), following the company's 3Q earnings results. CVS reported 3Q revenue of $38.6B vs. consensus $37.9B. Adj. EPS was $1.29, in line with consensus $1.29. Analyst Mohan Naidu believes that the margin outlook and lack of clarity on organic growth in... More

Leerink Partners Would Buy CVS Health (CVS) on Current Weakness

October 30, 2015 1:39 PM EDT

Leerink Partners reiterated an Outperform rating and $125.00 price target on CVS Health (NYSE: CVS) following the company's 3Q earnings and conference call. Management highlighted that the core business continues to grow at a healthy rate. While 2016E EPS guidance is below consensus expectations, management reiterated that their longterm adjusted EPS growth... More

CVS Health (CVS) Reports In-Line Q3 EPS; Issues Light FY16 EPS Outlook

October 30, 2015 6:52 AM EDT

CVS Health (NYSE: CVS) reported Q3 EPS of $1.29, in-line with the analyst estimate of $1.29. Revenue for the quarter came in at $38.5 billion versus the consensus estimate of $37.81 billion.

Same store sales for the retail drugstores increased 1.7% versus the third quarter of last year, with pharmacy same store sales up 4.6% and pharmacy same store prescription volumes up 4.4% on a 30-day equivalent basis. Pharmacy same store sales were negatively... More